Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Optimizing chemotherapy regimens for patients with early-stage breast cancer.

Dotan E, Goldstein LJ.

Clin Breast Cancer. 2010;10 Suppl 1:E8-15. doi: 10.3816/CBC.2010.s.002. Review.

PMID:
20587409
2.

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.

Cancer Res. 2002 Aug 15;62(16):4617-22.

3.

A new look at node-negative breast cancer.

Harbeck N, Thomssen C.

Oncologist. 2010;15 Suppl 5:29-38. doi: 10.1634/theoncologist.2010-S5-29.

4.

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.

Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA.

Clin Breast Cancer. 2004 Dec;5(5):348-52. Review.

PMID:
15585071
5.

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group.

J Natl Cancer Inst. 2001 Jun 20;93(12):913-20.

PMID:
11416112
6.

Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.

Jänicke F.

Clin Breast Cancer. 2000 Sep;1 Suppl 1:S57-61. Review.

PMID:
11970751
7.

Plasminogen activator proteins tested as prognostic markers.

Nelson NJ.

J Natl Cancer Inst. 2000 Jun 7;92(11):866-8. No abstract available.

PMID:
10841817
8.

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.

Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.

Thromb Haemost. 2004 Mar;91(3):450-6. Review.

PMID:
14983219
9.
10.

Anthracyclines in early-stage breast cancer: is it the end of an era?

Robson D, Verma S.

Oncologist. 2009 Oct;14(10):950-8. doi: 10.1634/theoncologist.2008-0070. Epub 2009 Jun 26. Review. Erratum in: Oncologist. 2009 Dec;14(12):1252.

11.

Prognostic and predictive factors in early-stage breast cancer.

Cianfrocca M, Goldstein LJ.

Oncologist. 2004;9(6):606-16. Review.

12.

High levels of uPA and PAI-1 predict a good response to anthracyclines.

Pritchard KI.

Breast Cancer Res Treat. 2010 Jun;121(3):625-6. doi: 10.1007/s10549-010-0795-1. Epub 2010 Feb 23. No abstract available.

PMID:
20177965
13.

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P.

J Natl Cancer Inst. 2008 Jan 2;100(1):14-20. Epub 2007 Dec 25.

PMID:
18159072
14.

Anthracyclines and the tailoring of treatment for early breast cancer.

Piccart-Gebhart MJ.

N Engl J Med. 2006 May 18;354(20):2177-9. No abstract available.

PMID:
16707755
16.

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.

J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.

PMID:
16682728
17.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, Jönsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
18.
19.
20.

PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.

Lei H, Hemminki K, Johansson R, Altieri A, Enquist K, Henriksson R, Lenner P, Försti A.

Breast Cancer Res Treat. 2008 May;109(1):165-75. Epub 2007 Jul 7.

PMID:
17616807

Supplemental Content

Support Center